---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-078781"
form_type: "8-K"
ticker: "JSPR"
cik: "0001788028"
company_name: "Jasper Therapeutics, Inc."
filed_at: "2026-07-16T21:15:34+00:00"
generated_at: "2026-07-16T21:16:04.059284+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Jasper Therapeutics completes all-stock acquisition of Kira Pharmaceuticals and $132M PIPE

## Summary
- Jasper acquires Kira in all-stock deal; pre-deal Jasper holders own ~6.68%, Kira holders ~49.86%, PIPE investors ~43.46% of combined company.
- Concurrent $132M private placement co-led by Affinity Asset Advisors and Ikarian Capital; expected to close July 20, 2026.
- Kira out-licenses KP-301 and KP-402 to Mirador Therapeutics for $12M upfront plus potential milestones.
- Combined company cash runway through H2 2028; key milestones include KP-104 Phase 2 renal data in Q4 2026 and end-of-Phase 2 FDA meeting for PNH in H1 2027.
- Briquilimab pre-BLA meeting for SCID expected in Q1 2027; KP-701 IND/CTA filing in Q1 2027 with first-in-human data in Q3 2027.

## SEC filing metadata
- accession: 0001213900-26-078781
- form_type: 8-K
- ticker: JSPR
- cik: 0001788028
- company_name: Jasper Therapeutics, Inc.
- filed_at: 2026-07-16T21:15:34+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/0001213900-26-078781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1788028/000121390026078781/ea0298316-8k_jasper.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-078781
- JSON: https://secwatch.observer/filing/0001213900-26-078781.json
- Plain text: https://secwatch.observer/filing/0001213900-26-078781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.